Estonian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
14 tulemused
Method to treat melanoma in BRAF inhibitor-resistant subjects
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
TECHNICAL FIELD
The in relates to methods to treat patients with melanoma, specifically those who have become resistant to B-Raf inhibitors. The treatments employ multikinase inhibitors, especially those that inhibit receptors for VEGF, PDGF, IGF and FGF.
BACKGROUND ART
It has been reported by
Method of treating melanoma
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
The present invention relates to novel compounds useful as therapeutic agents and assay reagents. More specifically, the present invention relates to a drug targeting and especially to a novel method of delivery of therapeutically active agents to tumour cells, in particular melanoma
Use of ERBB4 as a prognostic and therapeutic marker for melanoma
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
FIELD
This disclosure concerns the identification of novel mutations in members of the protein tyrosine (PTK) family, including ERBB4, and methods of use.
BACKGROUND
The protein tyrosine kinases (PTKs) are a family of proteins that catalyze phosphorylation of tyrosine residues in target proteins;
Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND OF THE INVENTION
Intercellular protein tyrosine phosphorylation is regulated by extracellular stimuli, such as cytokines, to control cell growth, differentiation and functional activities. This signaling mechanism depends on the interplay of protein tyrosine kinases, which initiate
Therapeutic compositions and methods useful in modulating protein tyrosine phosphatases
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
BACKGROUND OF THE INVENTION
Intercellular protein tyrosine phosphorylation is regulated by extracellular stimuli, such as cytokines, to control cell growth, differentiation and functional activities. This signaling mechanism depends on the interplay of protein tyrosine kinases, which initiate
Pyrido[2,3-b]pyrazin-8-substituted compounds and their use
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
TECHNICAL FIELD
The present invention pertains generally to the field of therapeutic compounds for treating proliferative disorders, cancer, etc., and more specifically to certain pyrido[2,3-b]pyrazin-8-substituted compounds, as described herein, which, inter alia, inhibit RAF (e.g., B-RAF)
Pyrido[2,3-B]pyrazin-8-substituted compounds and their use
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
TECHNICAL FIELD
The present invention pertains generally to the field of therapeutic compounds for treating proliferative disorders, cancer, etc., and more specifically to certain pyrido[2,3-b]pyrazin-8-substituted compounds, as described herein, which, inter alia, inhibit RAF (e.g., B-RAF)
Pyrido[2,3-B]pyrazin-8-substituted compounds and their use
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
RELATED APPLICATION
This application is related to U.S. provisional patent application No. 61/015,019 filed 19 Dec. 2007, the contents of which are incorporated herein by reference in their entirety.
TECHNICAL FIELD
The present invention pertains generally to the field of therapeutic compounds for
Pyrido[2,3-b]pyrazin-8-substituted compounds and their use
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
TECHNICAL FIELD
The present invention pertains generally to the field of therapeutic compounds for treating proliferative disorders, cancer, etc., and more specifically to certain pyrido[2,3-b]pyrazin-8-substituted compounds, as described herein, which, inter alia, inhibit RAF (e.g., B-RAF)
Aryl-quinolyl compounds and their use
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
TECHNICAL FIELD
The present invention pertains generally to the field of therapeutic compounds for treating proliferative disorders, cancer, etc., and more specifically to certain aryl-quinolyl compounds, as described herein, which, inter alia, inhibit RAF (e.g., B-RAF) activity. The present
Pyrido[2,3-b]pyrazin-8-substituted compounds and their use
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
TECHNICAL FIELD
The present invention pertains generally to the field of therapeutic compounds for treating proliferative disorders, cancer, etc., and more specifically to certain pyrido[2,3-b]pyrazin-8-substituted compounds, as described herein, which, inter alia, inhibit RAF (e.g., B-RAF)
Imidazo[4, 5-B]pyridin-2-one and oxazolo[4, 5-B] pyridin-2-one compounds and analogs thereof as cancer therapeutic compounds
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
RELATED APPLICATIONS
This application is a national stage filing under 35 U.S.C. 371 of International Application No. PCT/GB2007/001534 filed 26 Apr. 2007, which is related to: United Kingdom patent application number 0608268.9 filed 26 Apr. 2006 and U.S. patent application No. 60/745,633 filed 26
Inhibition of cell motility, angiogenesis, and metastasis
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
FIELD OF THE INVENTION
The present invention in general relates to a method of inhibiting cell motility and angiogenesis and treating various diseases in a mammal, and particularly to a method of inhibiting cell motility and angiogenesis induced by the hepatocyte growth factor (HGF). The present
Imidazo[4,5-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-one compounds and analogs thereof as therapeutic compounds
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
TECHNICAL FIELD
The present invention pertains generally to the field of therapeutic compounds for treating proliferative conditions, cancer, etc., and more specifically to certain imidazo[4,5-b]pyridin-2-one and oxazolo[4,5-b]pyridin-2-one compounds and analogs thereofwhich, inter alia, inhibit RAF
Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus
- Töötab 55 keeles
- Taimsed ravimid, mida toetab teadus
- Maitsetaimede äratundmine pildi järgi
- Interaktiivne GPS-kaart - märgistage ürdid asukohas (varsti)
- Lugege oma otsinguga seotud teaduspublikatsioone
- Otsige ravimtaimi nende mõju järgi
- Korraldage oma huvisid ja hoidke end kursis uudisteuuringute, kliiniliste uuringute ja patentidega
Sisestage sümptom või haigus ja lugege ravimtaimede kohta, mis võivad aidata, tippige ürdi ja vaadake haigusi ja sümptomeid, mille vastu seda kasutatakse.
* Kogu teave põhineb avaldatud teaduslikel uuringutel
